Brief: Actinium Pharma Reports 72% MRD Negativity Rate in Phase 1 Study of Actimab-A in Relapsed or Refractory AML

Actinium Pharmaceuticals

14/12/2021 13:14

Dec 14 (Reuters) - Actinium Pharmaceuticals Inc  ATNM.A :
    * ACTINIUM PHARMACEUTICALS, INC. ANNOUNCES 72% MRD
NEGATIVITY RATE
IN THE RECENTLY COMPLETED PHASE 1 STUDY OF ACTIMAB-A IN
COMBINATION WITH CLAG-M FOR PATIENTS WITH RELAPSED OR REFRACTORY
AML
    * ACTINIUM PHARMACEUTICALS INC - 60% RESPONSE RATE IN
PATIENTS
RECEIVING PRIOR VENETOCLAX AND HMA THERAPY INCLUDING 4 COMPLETE
REMISSIONS
    * ACTINIUM PHARMACEUTICALS INC - 10 COMPLETE REMISSIONS
REPORTED
AND AN 80% RESPONSE RATE ACROSS ALL DOSE COHORTS IN PATIENTS
RECEIVING LESS THAN 4 LINES OF PRIOR THERAPY
    * ACTINIUM PHARMACEUTICALS INC - HIGH MRD NEGATIVITY RATE
COMPARES
FAVORABLY TO 39% MRD NEGATIVITY RATE WITH CLAG-M ALONE IN PRIOR
STUDIES

Source text for Eikon:  ID:nPn45BQSca 
Further company coverage:  ATNM.A 

 ((Reuters.Briefs@thomsonreuters.com;))